Trajan Group Holdings Limited
Trajan Group Holdings Limited is recognized as a global leader in scientific measurement solutions, playing a foundational role in the microsampling devices market. As a top-tier company, Trajan specializes in developing and commercializing minimally invasive blood collection technologies, primarily through its Neoteryx microsampling solutions. The company’s flagship products include the Mitra® device, which utilizes proprietary Volumetric Absorptive Microsampling (VAMS®) technology, and the hemaPEN® device for high-precision Dried Blood Spot (DBS) sampling. Mitra’s VAMS technology is pivotal as it allows for easy, accurate, and remote collection of up to 120 µL of blood by non-professionals, eliminating the traditional blood hematocrit bias associated with conventional DBS and ensuring high data quality. These devices streamline the entire process from collection to lab analysis, drastically reducing the need for phlebotomy and cold-chain shipping. With manufacturing facilities across the US, Australia, Europe, and Asia, Trajan is strategically expanding its global distribution through partnerships, such as the agreement with CliniSciences, to make its user-friendly, high-precision tools a standard in clinical, pharmaceutical, and at-home diagnostic workflows, thereby accelerating personalized medicine and improving patient compliance.
Latest Market Research Report on Microsampling Devices Download PDF Brochure Now
Tasso, Inc.
Tasso, Inc. is a pioneering US-based company at the forefront of the non-invasive and minimally invasive blood collection segment of the microsampling market. The company’s core mission is to enable decentralized clinical trials and at-home diagnostics by creating user-friendly, on-demand blood collection devices. Tasso’s portfolio features its proprietary Tasso+ device, which is FDA cleared for both clinical and at-home use, simplifying blood collection from the upper arm without requiring a traditional venipuncture. This device is designed to collect liquid whole blood, plasma, or serum, a critical capability that many dried-spot microsampling methods cannot match. The Tasso+ is instrumental in managing chronic conditions remotely, as evidenced by its FDA clearance announcement in October 2024, which noted its role in making it easier for patients to manage their care from home. Tasso is also continually expanding its offerings to clinical trial services, integrating enhanced data analytics to support pharmaceutical and biotech partners. By consistently innovating in automated, patient-centric microsampling, Tasso ensures reliable data insights while drastically improving the convenience and compliance for patients globally.
YourBio Health, Inc.
YourBio Health, Inc. is a key player in the microsampling devices market, distinguished for its commitment to expanding patient access to non-invasive diagnostics through convenient, at-home blood collection solutions. Operating from the US, the company’s focus is on developing innovative technologies that allow consumers to collect high-quality blood samples easily and comfortably, thereby bridging the gap between patients and diagnostic testing centers. YourBio Health successfully received FDA 510(k) clearance in September 2023 for its new at-home blood collection device, which underscores its focus on regulatory compliance and bringing quality, innovative health solutions to the consumer health market. The company’s technology supports remote health monitoring and self-diagnosis, which is essential as more individuals seek easy access to at-home sample collection. As a leader in the at-home blood collection devices market, YourBio Health is instrumental in empowering patients with restricted access to traditional healthcare facilities to participate fully in their health monitoring and chronic disease management, driving the trend toward decentralized and patient-centric healthcare.
Capitainer AB
Capitainer AB, based in Sweden, is an innovative provider in the microsampling devices market, specializing in solutions that overcome the historical limitations of traditional Dried Blood Spot (DBS) sampling. The company’s proprietary technology is built around the qDBS® device line, which includes the Capitainer-B and Capitainer-B50. These devices are designed to collect a precise, volumetric sample of blood (e.g., 10 µL or 50 µL) from a finger or heel stick and protect the dried sample from external contamination. Capitainer’s technology ensures accurate volumetric uptake and enhanced sample stability, delivering reliable data to laboratory technicians, which is crucial for applications like therapeutic drug monitoring and infectious disease testing. The company’s focus on simplified user interfaces makes its devices highly recommended for home use, streamlining the logistics of sample collection and transport for both clinical and non-clinical research. The receipt of CE marking for its qDBS® device in August 2024 facilitates its distribution across European markets, confirming Capitainer’s role in advancing high-quality, standardized, and volumetric microsampling technology globally.
BD (Becton, Dickinson, and Company)
BD (Becton, Dickinson, and Company) is a globally recognized medical technology leader and is consistently ranked as a major market leader in the Global Blood Micro-Sampling Medical Devices Market. With an expansive product portfolio, BD’s involvement in microsampling is primarily focused on delivering devices that enhance patient safety, increase user convenience, and maintain high standards of clinical efficacy. The company provides a comprehensive range of microsampling essentials, including safer, more reliable lancets, advanced capillary blood sampling devices, and complete micro-sampling kits. BD’s continuous developmental efforts are centered on improving the experience of blood collection, ensuring minimal invasiveness while maintaining specimen quality. Their devices are broadly used across the healthcare ecosystem, including hospitals, clinics, diagnostic laboratories, and in-home healthcare settings. By integrating patient safety and operational efficiency into its design philosophy, BD’s established presence and technological advancements solidify its critical role in supplying the foundational infrastructure for blood collection, from traditional phlebotomy to modern microsampling.
Abbott Laboratories
Abbott Laboratories is a leading global healthcare company that leverages advanced technology, including micro-sampling, to deliver cutting-edge diagnostic and monitoring solutions. A key player in the micro-sampling market, Abbott focuses on integrating this technology to improve the accuracy and usability of its point-of-care and at-home monitoring systems. The most prominent example is the company’s world-leading FreeStyle Libre glucose monitoring system, which uses micro-sampling principles for continuous, minimally invasive glucose measurement. In September 2024, Abbott launched an upgraded version of the FreeStyle Libre, integrating more advanced micro-sampling technology to specifically enhance accuracy and user comfort for millions of diabetes patients worldwide. By continuously refining the micro-sampling components within its devices, Abbott is able to provide quick, reliable, and user-friendly testing with minimal sample volumes, reinforcing its position as an innovator in accessible healthcare and home healthcare management.
Thermo Fisher Scientific
Thermo Fisher Scientific is a globally dominant provider of scientific solutions, with significant capabilities that make it a key player in the microsampling devices market. The company’s strength lies in integrating micro-sampling technology across its vast ecosystem of instruments, reagents, and services for life sciences research and clinical diagnostics. Thermo Fisher is strategically focused on the high-growth area of genomic testing, leveraging microsampling to facilitate efficient and accurate genetic analysis from tiny blood volumes. This commitment was highlighted in May 2024 when the company announced a strategic partnership with a biotech firm specifically to develop a new line of blood micro-sampling devices tailored for genomic testing applications. By focusing on enabling personalized medicine through high-quality sample collection and analysis, Thermo Fisher provides the essential technological infrastructure that allows researchers and clinicians to accelerate drug discovery, diagnostics development, and fundamental biological research with high-throughput and reliable results.
F. Hoffmann-La Roche Ltd (Roche Diagnostics)
F. Hoffmann-La Roche Ltd (Roche) is a major pharmaceutical and diagnostics industry leader, and its diagnostics division is a critical force in the microsampling devices market. Roche’s strategy is to integrate robust diagnostic systems with technologies that enhance patient compliance and testing accessibility. In the microsampling sector, Roche Diagnostics is noted for introducing new developments aimed at patient comfort and chronic disease management. A significant contribution was the July 2024 launch of a next-generation lancet-based micro-sampling device. This device was specifically developed to offer a less invasive and more comfortable blood collection method, thereby improving patient adherence to chronic disease management protocols. Roche focuses on ensuring its micro-sampling solutions are reliable and high-quality, bridging the technical requirements of clinical analysis with the practical needs of at-home or point-of-care testing, and thus driving innovation in both molecular and immunological testing for patient care globally.
PerkinElmer
PerkinElmer Inc. is a globally recognized corporation and a key player in the Global Blood Micro-Sampling Medical Devices Market, deeply involved in diagnostics, life sciences, and analytical instrumentation. The company’s expertise in microsampling centers on developing and providing specialized solutions for the precise and highly efficient manipulation of small-volume fluids, a capability critical for modern scientific and clinical applications. While operating across a broad portfolio, PerkinElmer’s platforms are instrumental in enhancing throughput and reproducibility in complex laboratory workflows, often leveraging miniaturization to achieve these goals. In the context of micro-sampling, the company provides instruments and consumables that support vital processes in areas such as newborn screening, genomics, and advanced compound screening. PerkinElmer’s focus on innovative design and precision tools helps researchers and clinicians streamline complex workflows, thereby reinforcing its reputation as an essential provider of infrastructure for advancements in personalized medicine and fundamental biological research.
A. Menarini Diagnostics
A. Menarini Diagnostics, part of the international Menarini Group, is a prominent player in the European diagnostics sector and a recognized company in the microsampling market. The company is committed to expanding the accessibility of diagnostic testing, particularly through developing user-friendly, point-of-care (POC) solutions that rely on small-volume samples. A notable contribution to the microsampling market was the July 2023 launch of a new microsampling solution specifically designed for infectious disease testing. This initiative demonstrates Menarini Diagnostics’ focus on leveraging simple sample collection methods to improve the reach and speed of essential diagnostic testing, especially in decentralized settings. By providing these accessible microsampling solutions, the company helps healthcare professionals streamline workflows and deliver rapid, reliable results closer to the patient, validating its importance in driving the adoption of efficient, high-quality diagnostics across various European markets.
Latest Market Research Report on Microsampling Devices Download PDF Brochure Now